Standardized Protocol Is Associated With a Decrease in Continuous Albuterol Use and Length of Stay in Critical Status Asthmaticus*
Conclusions: Implementation of a quality improvement protocol in critically ill patients with status asthmaticus was associated with a decrease in continuous albuterol duration and hospital length of stay.
His group will study how abnormal calcium signals may contribute to human diseases such as allergies and asthma. (read more)
VERDICT: It is unclear if people with asthma are at increased risk of contracting COVID-19 or of worse outcomes from COVID-19 infection. The evidence available is limited with some sources suggesting an underrepresentation of PWA in hospitalised cases, and others showing an increased risk of worse outcomes in PWA which may be associated with disease severity. Consensus broadly holds that asthma medications should be continued as usual. Asthma care may be disrupted during the pandemic; self-management and remote interventions may be of benefit but have not been tested in this context.
Condition: Asthma Interventions: Drug: CSJ117; Drug: Placebo Sponsor: Novartis Pharmaceuticals Not yet recruiting
Condition: Asthma Attack Intervention: Other: Interview Sponsor: University of Nottingham Not yet recruiting
Asthma can vary greatly from person to person, with differences in severity and frequency of attacks as well as what triggers those attacks.
Recent research found women with COPD and asthma—even those who have never smoked—are at a higher risk of developing rheumatoid arthritis...
Pressurised metered dose inhalers (pMDIs) are effective drug delivery devices prescribed in obstructive airway diseases due to their convenience, portability, ease of enabling multiple doses in a single formulation, and storage in any orientation. For the management of asthma, the fixed-dose combination of a long-acting β2-agonist (LABA) and an inhaled corticosteroid (ICS) has been recommended by Global Initiative for Asthma guideline as a preferred treatment option for patients who are uncontrolled with only ICS doses.
The Coronavirus Disease 2019 (COVID-19) pandemic has created unique challenges for emergency care providers and patients alike. While the rise in COVID-19 patients requiring inpatient care has led to overcrowding in some emergency departments (ED), discharging stable patients from the ED has also become more complicated in the COVID-19 era . Prior to COVID-19, patients often used EDs for low acuity conditions (e.g., asthma, cellulitis, urinary tract infection) that are treatable with short courses of outpatient medications.
Matthew Greenhawt is supported by grant #5K08HS024599-02 from the Agency for Healthcare Research and Quality; is an expert panel and coordinating committee member of the NIAID-sponsored Guidelines for Peanut Allergy Prevention; has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV Technologies, Sanofi/Genzyme, Genentech, Nutricia, Kaleo Pharmaceutical, Nestle, Aquestive, Allergy Therapeutics, Allergenis, Aravax, Glaxo Smith Kline, Prota, and Monsanto; is a member of the scientific...
Chronic pruritus, or itch lasting>6 weeks, is a common symptom and has a profoundly negative impact on quality of life. While many primary dermatologic disorders such as atopic dermatitis and chronic urticaria are characterized by pruritus, numerous other allergic, hepatobiliary, lymphoproliferative, neurologic, and renal disorders are associated with chronic pruritus. Itch involves complex interactions orchestrated by a variety of factors released from and acting on the skin, immune system, and the sensory nervous system.